Floatz logo

45 assets in T-Lymphoblastic Lymphoma

Therapeutic assets addressing T-Lymphoblastic Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Vincristine Sulfate
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (70)
Pegaspargase
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (68)
Cyclophosphamide
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (67)
Dexasone
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (67)
Daunomycin
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (66)
Mercaptopurine Anhydrous
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (66)
Methotrexate
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (66)
Thioguanine Anhydrous
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (66)
Adriamycin
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (65)
Cytarabine
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (65)
Prednisone
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (65)
Nelarabine
T-Lymphoblastic Lymphoma
Children's Oncology GroupP3BB (64)
Calaspargase Pegol
T-Lymphoblastic Lymphoma
Children's Oncology GroupP2/3B (60)
Daratumumab
T-Lymphoblastic Lymphoma
Children's Oncology GroupP2/3B (60)
Fludarabine
T-Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2B (60)
(+)-Vincristine
T-Lymphoblastic Lymphoma
National Cancer Institute (NCI)P2B (60)
Venetoclax
T-Lymphoblastic Lymphoma
National Cancer Institute (NCI)P2B (58)
Bortezomib
T-Lymphoblastic Lymphoma
Children's Oncology GroupP2/3CCC (55)
Hydrocortisone
T-Lymphoblastic Lymphoma
Children's Oncology GroupP2/3CCC (55)
Prednisolone
T-Lymphoblastic Lymphoma
Children's Oncology GroupP2/3CCC (55)
cd7.car/28zeta car t cells
T-Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP1/2CCC (54)
cd7-specific car gene-engineered t cells
T-Lymphoblastic Lymphoma
Shenzhen Geno-Immune Medical InstituteP1/2CCC (54)
Navitoclax
T-Lymphoblastic Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Obi 3424
T-Lymphoblastic Lymphoma
SWOG Cancer Research NetworkP1/2CCC (48)
cd19-ucart
T-Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP1CC (46)
Autologous Bcma/Cd19 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Autologous Cd5/Cd7 Dual-Target Car-T Module
T-Lymphoblastic Lymphoma
Beijing BiotechP1/2CC (45)
Linperlisib
T-Lymphoblastic Lymphoma
Beijing Tongren HospitalP1/2CC (45)
Allogeneic Cd5.Car/28Zeta Car T Cells
T-Lymphoblastic Lymphoma
Baylor College of MedicineP1CC (43)
bt-007 cd7 car-t cells
T-Lymphoblastic Lymphoma
Bioceltech Therapeutics, Ltd.P1CC (43)
Carccr9 T Cells
T-Lymphoblastic Lymphoma
University College, LondonP1CC (43)
cd1a-car t
T-Lymphoblastic Lymphoma
OneChain ImmunotherapeuticsP1CC (43)
Xmab18968
T-Lymphoblastic Lymphoma
Ehab L AtallahP1CC (43)
Busulfanum
T-Lymphoblastic Lymphoma
Ossium Health, Inc.P1CC (41)
Mesna
T-Lymphoblastic Lymphoma
Ossium Health, Inc.P1CC (41)
Sirolimus
T-Lymphoblastic Lymphoma
Ossium Health, Inc.P1CC (41)
cd5-targeted car-t cells
T-Lymphoblastic Lymphoma
Zhejiang UniversityEarly P1C (38)
Target Cd7 Car-T Cells
T-Lymphoblastic Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaEarly P1C (38)
Nivestim
T-Lymphoblastic Lymphoma
Ossium Health, Inc.P2NR ()